Background: Refractory breathlessness in advanced chronic disease leads to high levels of disability, anxiety and social isolation. These result in high health-resource use, although this is not quantified. Aims: To measure the cost of care for patients with advanced disease and refractory breathlessness and to identify factors associated with high costs. Design: A cross-sectional secondary analysis of data from a randomised controlled trial. Setting/participants: Patients with advanced chronic disease and refractory breathlessness recruited from three National Health Service hospitals and via general practitioners in South London. Results: Of 105 patients recruited, the mean cost of formal care was £3253 (standard deviation £3652) for 3 months. The largest contributions to formal-care cost were hospital admissions (>60%), and palliative care contributed <1%. When informal care was included, the total cost increased by >250% to £11,507 (standard deviation £9911). Increased patient disability resulting from breathlessness was associated with high cost (£629 per unit increase in disability score; p = 0.006). Increased breathlessness on exertion and the presence of an informal carer were also significantly associated with high cost. Patients with chronic obstructive pulmonary disease tended to have higher healthcare costs than other patients. Conclusion: Informal carers contribute significantly to the care of patients with advanced disease and refractory breathlessness. Disability resulting from breathlessness is an important clinical cost driver. It is important for policy makers to support and acknowledge the contributions of informal carers. Further research is required to assess the clinical-and cost-effectiveness of palliative care interventions in reducing disability resulting from breathlessness in this patient group.
Introduction
Breathlessness is a common and distressing symptom affecting many people with advanced chronic disease. It causes substantial disability, anxiety and social isolation and is difficult to treat. [1] [2] [3] [4] Globally, over 75 million people have breathlessness annually, including over 58 million people with severe lung disease, 5 more than 5 million people with incurable cancer and more than 12 million people with heart failure. 6, 7 The high symptom burden and progressive nature of refractory breathlessness in advanced disease suggest that patients will require increasing help from professionals and family members. As the underlying disease progresses, breathlessness increases and is accompanied by panic. 8, 9 This is terrifying for patients and their families and often results in emergency hospital admissions. 9 Despite the concerns about the large resource inputs for these patients, there is no evidence on the costs of care for them. Thus, it is important to establish the costs of caring for people with advanced disease and refractory breathlessness. Such information is vital to understand the likely 'burden' of the condition and to provide a baseline to assess the relative economic impact of different treatments. It is conceivable that costs will arise as a result of direct healthcare input and care provided by other agencies, such as social care services. Some unpaid care will also frequently be provided by family members and/or friends (informal care), and this has never been quantified.
The aims of this study were to measure the formal and informal costs of care for patients with advanced disease and refractory breathlessness and to identify patient and clinical factors associated with high costs.
Materials and methods

Design
This study is a cross-sectional secondary analysis of data from a randomised controlled parallel-group, pragmatic, single-blind fast-track trial (ClinicalTrials.gov, number NCT01165034). 4 The main study, and also this study, had ethical approval from the King's College Hospital Ethics Committee (Ref. 10/H0808/17). Participants provided their written consent to participate in the main study. The data set used for this cross-sectional secondary analysis was anonymised and de-identified prior to analysis. This procedure was approved by the Ethics Committee.
Setting and sample
Study participants were included according to a standard proforma completed by the identifying clinician. Details of the trial have been published elsewhere. 4 But in summary, participants were adult patients (⩾18 years) with advanced disease (e.g. cancer, chronic obstructive pulmonary disease (COPD), chronic heart failure, interstitial lung disease (ILD) and motor neuron disease) and refractory breathlessness on exertion or rest (Medical Research Council (MRC) dyspnoea scale score ⩾2), despite optimum treatment of the underlying disease, as deemed by the identifying clinician. Participants were recruited from three large teaching hospitals and via general practitioners (GPs) in South London.
Procedures
In the main study, data were collected at study entry by trained interviewers, usually in participants' homes. The data set used for this cross-sectional secondary analysis was collected during the main trial. This data set was anonymised and de-identified prior to analysis and comprises demographic, clinical outcome assessments and use of healthcare services including the Chronic Respiratory Disease Questionnaire (CRQ); 10, 11 Numerical Rating Scale (NRS), average, at rest and on exertion; 12 London Chest Activity of Daily Living (LCADL), a questionnaire of the level of disability induced by breathlessness; 12 EuroQol five dimensions questionnaire (EQ-5D) (three levels); 12 Palliative care Outcome Scale (POS), a 10-item measure for advanced disease widely validated in cancer and noncancer; 13 Hospital Anxiety and Depression Scale (HADS); 14 and the breathlessness version of the Client Services Receipt Inventory 15 (CSRI) which has been provided in Supplementary File S1. Details of other procedures conducted in the main trial have been published elsewhere. 4 
Clinical outcomes
Study outcomes included breathlessness mastery (using a sub-domain of the CRQ); severity of breathlessness on exertion in the previous 24 h, disability (LCADL); healthrelated quality of life (EQ-5D); palliative needs (POS); breathlessness, fatigue and emotional function (other domains of the CRQ); anxiety and depression (HADS) and lung function (spirometer).
Service use and cost
A broad costing perspective was taken with services including those provided by health and social care agencies and also informal carers. However, societal costs were not calculated as this analysis did not include lost productivity. In this analysis, formal care comprised both direct health care and social care. Service use was measured at study entry using a version of the Client Service Receipt Inventory (CSRI). 15 Patients gave details of services used during the 3 months prior to study entry.
Services included hospital care, primary health care, social care, the provision of aids and home adaptations and informal care provided by family members and/or friends. Length of hospital admission was recorded, while the number of contacts and, where relevant, the mean length of these contacts were documented for other services. Information was provided on the number of hours that family/friends spent providing personal care and help in and outside the home and in other tasks, per week.
Costs were calculated by combining resource use data with unit costs obtained from standard sources such as the National Health Service (NHS) reference cost data 16 or the Unit Costs of Health and Social Care (Personal Social Services Research Unit (PSSRU)), 17 where applicable. We assumed that in the absence of an informal carer, social services would need to provide home care, and therefore, the unit cost of a home care worker was used as proxy for informal care. Missing values for quantities of resource use were imputed using multiple imputation by chained equations (MICE) via the 'ice' command in Stata. 18, 19 
Statistical analysis
We compared formal and informal health-resource use and cost across primary diagnosis using descriptive statistics. We used scatter and box plots to graphically examine variations in costs and Spearman's Rho to assess correlations.
We used generalised linear models (GLM) to determine which factors were associated with cost. The dependent variable was cost, while clinical and demographic variables were used as independent variables. Age and EQ-5D index were centred to means to enable appropriate interpretation of intercepts. Spearman's rank correlations of the independent variables were used to determine whether any variables were highly correlated and therefore not recommended for inclusion in the same regression model. A high correlation was defined as a correlation coefficient >|0.7|. 20 Where two or more independent variables were found to be highly correlated, we conducted univariate analysis with the dependent variable and selected the independent variable with highest adjusted R 2 . Separate regression models were fitted for total cost, health service cost and informal care cost. We used the modified Park test 21 and the modified Hosmer-Lemeshow test 22 to determine the appropriate combination of link function and distributional family. The analysis was performed using STATA release 13. 23 This study was reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement for cross-sectional studies.
Regression equation
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where ∝ i is the linear predictor formed from explanatory variables and coefficients. ε i follows gamma distribution which has an increasing variation with larger mean.
, where g is the link function.
Results
In all, 105 patients were recruited. The mean age was 67 years, 61 (58%) were men, over half (54%) had COPD, 20% had cancer, 18% had ILD, 5% had heart failure and 3% had other diseases. Patients had severe disease: forced expiratory volume (FEV 1 ) was 46% predicted, vital capacity (VC) 58% predicted, oxygen saturation at rest 93%, average breathlessness 5.9/10 and on exertion 8.3/10. Their mean EQ-5D index score was 0.35, and their average total Palliative care Outcome Score was 15/40, indicating a disabled group with poor quality of life (see Table 1 ).
The results show high levels of outpatient visits, GP contacts, inpatient care and accident and emergency attendance. More than 75% received care from family and friends (Table 2 ). The mean total cost of care per patient was £11,507 (standard deviation (SD) £9911). Informal care accounted for over 70% of this.
Over 64% of informal care cost was accounted for by the number of hours: on call (45%), providing help inside the home (9%) and providing personal care (8%). Over 60% of direct healthcare cost was accounted for by hospital admissions (inpatient care 49.3% and critical care 11%). Palliative care (home palliative care and hospice) accounted for less than 1% of direct healthcare cost, and rehabilitation and other therapies accounted for less than 5% (Table 2 ). Over 68% of social care cost was spent on providing special beds (52%) and wheel chairs (17%).
Overall, there was a high variation in cost with more variation in the cost of informal care when compared to formal care, across all diagnoses. The variability in healthcare cost was largest for COPD patients (range: £53-£22,178), whereas cancer patients had the highest variability in informal care cost (range: £0-£43,536) ( Figure 1) .
We found no correlation between direct healthcare and informal care costs (Figure 2) .
The following independent variables were found to be highly correlated (Spearman's Rho >0.78): three variables FEV 1 percent predicted, VC percent predicted and CRQ dyspnoea and also between NRS average, NRS breathlessness at rest and NRS on exertion. FEV1 percent predicted and NRS on exertion were selected as they each had higher adjusted R 2 values in univariate analysis with cost.
The results of GLM regression showed that disability resulting from breathlessness was significantly associated with high total cost (£629 per unit increase in LCADL total score; p = 0.006) as well as informal and direct healthcare costs ( Table 3 ). The presence of an informal carer was also significantly associated with high total and informal-care cost. Increased breathlessness on exertion was associated with increased healthcare cost; no other clinical variable was significantly associated with cost. Patients with COPD tended to have higher healthcare costs than patients with cancer, ILD or heart failure ( Table 3) .
Discussion
This is the first study that examines the cost of care in patients with advanced disease and refractory breathlessness. Over a period of 3 months, hospital admissions (inpatient and critical-care stays) had the largest contribution to direct healthcare cost (>60%), whereas palliative care and rehabilitation accounted for less than 1% and 5%, respectively. High healthcare cost was associated with increasing disability resulting from breathlessness, breathlessness on exertion and a diagnosis of COPD. When informal care was included, the total cost of care increased by >250%. We also found wide variations in cost.
In these 105 patients with advanced disease and refractory breathlessness, we found that the cost of formal care was £3253 (equivalent to US$4593.70: using 2014 Organisation for Economic Co-operation and Development (OECD) purchasing power parities (PPP) conversion rate) over a period of 3 months. This was mainly accounted for by inpatient care, critical-care and outpatient clinics. It is difficult to compare our estimates with other studies (or patients) because no other studies have examined the cost of care in patients with advanced disease and refractory breathlessness. Nevertheless, the cost estimates we observed appear to be higher than the costs observed in studies in people with COPD. In the 2011 systematic review by Bustacchini et al., 24 which explored the economic burden of COPD in those aged 60 years or older, mean healthcare costs at 3 months ranged from £540.98 (US$763.94) in the United States to £2535.69 (US$3580.75) in Australia (inflated for the purpose of this comparison from 2010 US$ to 2014 GBP using standard conversion formulae). Inpatient care was the main driver of healthcare cost in the Bustacchini et al. 24 review. Our study suggests that the cost of formal care for people with advanced disease and refractory breathlessness is very high (more expensive than the cost of COPD). This perhaps is a reflection of the high cost of care in the last year of life; 25% of annual Medicare hospital costs are spent on people in the last year of life in the United States, while in the United Kingdom, up to 29% of NHS hospital expenditures are for people who are in the last year of life. 25 This is the first study to quantify the informal care cost of advanced disease and refractory breathlessness. We found that the cost of informal care in our study was high. Including informal care increased the total cost per patient by over 250% from £3253 (US$4593.70) to £11,507 (US$16,249.52). Informal care was mainly accounted for by the time spent supervising a patient (hours on call), and to a lesser extent, bathing, dressing, cooking and cleaning. This highlights the importance of informal care particular in advanced disease. It is essential to account for informal care cost because in the absence of informal carers, possibly the same amount of care would need to be provided by formal carers via health or social care services. For example, certain patients (e.g. patients on medical equipment like tracheostomies or non-invasive ventilation or at risk of falls) will require 24-h supervision. In the United Kingdom, if such patients do not have informal carers, then often they are cared for in care-homes where they are supervised by formal carers, and the health service bears the cost. However, it is conceivable that the time spent on supervision reported in this study for some patients may have been more than what would have been required had such supervision been provided by formal carers. Nevertheless, if the cost of supervising patients was completely excluded from our analysis, informal care would still account for more than 50% of the total cost of care. Conversely, it is possible that informal carers may have underestimated how much time they spent supervising. If cost of supervision was assumed to be at the maximum for all carers (£12,479), then informal care cost would account for more than 82% of the total cost of care per patient.
High healthcare cost was associated with increasing disability resulting from breathlessness and breathlessness on exertion. Also, the healthcare cost for COPD was significantly more than lung cancer, ILD. Our results are supported by evidence from several studies on COPD patients which suggest that increased disability and poor physical performance are both independently associated with increased healthcare utilisation, particularly the risk of hospital re-admission. [26] [27] [28] [29] [30] [31] [32] Further research is required to assess the effectiveness and cost-effectiveness of palliative care interventions in reducing disability resulting from breathlessness in patients with advanced disease and refractory breathlessness. The presence of a career was found to be associated with high cost (both total and informal-care costs) as is to be expected. Also, we found a high variation in cost with more variation in the cost of informal care when compared to formal care. We cannot explain this high variation based on our data. However, it is conceivable that such variation is either due to random variation or, more likely, due to specific factors that we have not measured. We believe palliative care may reduce some of this variation. Palliative care has been shown to decrease rates of emergency department attendance 33 and length of hospital stay and to increase home-death rates, quality of life and possibly survival in patients with advanced illness. 4 Our study has limitations. First, we did not account for drugs in our estimates but assumed that these are included in the cost of care, and so, we may have underestimated the full cost of care. Studies in elderly patients with COPD suggest that pharmaceutical agents may have a moderate to high impact on costs. 24 Second, we did not obtain resource use estimates from medical records but rather relied on self-report which may have introduced recall bias. However, self-report of service use has been shown to be reliable. 15, 34 Third, we had to assume a proxy cost for informal care. In the absence of informal carers, it is unlikely that all patients would have received help from social services, but the cost of a home care worker should nevertheless indicate the value of this informal care. Fourth, the regression model only included data recorded as part of the study. It is likely that other unmeasured patient characteristics could have had some impact on cost. Fifth, our study was also limited by a small sample size which made it difficult to conduct more extensive analyses, particularly for some disease groups (such as cardiac failure where we had only five patients). Finally, the data in our study were highly skewed and there were a number of 'zero' resource use data (i.e. instances where costs were '£0' because patients did not use any resources), which both reduce the power to detect a significant difference. It is conceivable that a larger study would highlight other cost drivers in this group.
This study provides the first evidence on the costs of caring for people with advanced disease and refractory breathlessness; it highlights the likely 'burden' of the condition and provides a baseline for assessing the relative economic impact of different treatments in future studies. Further research is required to assess the effectiveness and cost-effectiveness of palliative care interventions in reducing disability resulting from breathlessness in patients with advanced disease and refractory breathlessness.
